2004
DOI: 10.1016/j.ijpharm.2004.02.023
|View full text |Cite
|
Sign up to set email alerts
|

Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
30
0
3

Year Published

2007
2007
2015
2015

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 56 publications
(34 citation statements)
references
References 21 publications
1
30
0
3
Order By: Relevance
“…The concentration range of free 5-FU was selected based on preliminary experiments, in which increasing concentrations of 5-drug from 0.01 µM to 1 mM were tested in culture. Those drug concentrations were in accordance with data reported in the literature [33][34][35]. The administration of 5-FU 10 μM in solution produced a decrease of the percentage of viability in MCF7 cells, which was between 91 ± 8% and 43 ± 3% after 3 days of incubation.…”
Section: Cell Culture Studiessupporting
confidence: 91%
“…The concentration range of free 5-FU was selected based on preliminary experiments, in which increasing concentrations of 5-drug from 0.01 µM to 1 mM were tested in culture. Those drug concentrations were in accordance with data reported in the literature [33][34][35]. The administration of 5-FU 10 μM in solution produced a decrease of the percentage of viability in MCF7 cells, which was between 91 ± 8% and 43 ± 3% after 3 days of incubation.…”
Section: Cell Culture Studiessupporting
confidence: 91%
“…Diversos trabalhos comprovaram o aumento da efi cácia e a redução da toxicidade de substâncias bioativas de origem natural ou sintética, administrados em lipossomas (Ratner, 2002), sistemas nanoparticulados (Feng et al, 2004;Berkland et al, 2002) ou micropartículas (Gupte;Ciftci, 2004;Ribeiro-Costa et al, 2004). Relatos recentes demonstram a atividade antitumoral do taxol (Gupte;Ciftci, 2004) e do ácido úsnico (Cladonia substellata) em microesferas (Ribeiro-Costa et al, 2004), da lectina de Cratylia mollis encapsulada em lipossomas (Andrade et al, 2004), de xantonas (Teixeira et al, 2005), da doxorrubicina em nanopartículas (Barraud et al, 2005) e 5-fl uorouracil em lipossomas (Jin et al, 2005), atividade antiparasitária do praziquantel em lipossomas (Mourão et al, 2005), atividade antibiótica da vancomicina em micropartículas (Le Ray et al, 2005) e anfotericina B em lipossomas (Bellocchio et al, 2005), atividade hipoglicemiante da insulina em micropartículas (Kim et al, 2005) e anti-estrógenos em lipossomas e nanopartículas para tratamento do câncer de mama (Maillard et al, 2005;Memisoglu-Bilensoy et al, 2005).…”
Section: Toxicidade E Viabilização Da Biodisponibilização Da Dctnunclassified
“…It is a fluorinated analog of pyrmidine base uracil, which is metabolized intracellulary to its active form, fluorodeoxyuridine monophophate (FdUMP). The active form inhibits DNA synthesis by inhibiting the normal production of thymidine (Gupte & Ciftci, 2004).…”
Section: Introductionmentioning
confidence: 99%